These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1674950)

  • 21. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 22. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
    Kantrowitz JT; Srihari VH; Tek C
    J Clin Psychopharmacol; 2007 Oct; 27(5):525-6. PubMed ID: 17873695
    [No Abstract]   [Full Text] [Related]  

  • 33. [Improvement of tardive dyskinesia with high doses of propranolol].
    Moreira MJ; Karniol IG
    Rev Paul Med; 1979; 93(3-4):76-8. PubMed ID: 40299
    [No Abstract]   [Full Text] [Related]  

  • 34. Nifedipine in the treatment of tardive dyskinesia.
    Duncan E; Adler L; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Dec; 10(6):414-6. PubMed ID: 1981070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of nilvadipine in two cases of chronic schizophrenia.
    Yamada K; Ashikari I; Onishi K; Kanba S; Yagi G; Asai M
    Psychiatry Clin Neurosci; 1995 Aug; 49(4):237-8. PubMed ID: 9179944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of clozapine on preexisting tardive dyskinesia.
    Littrell K; Magill AM
    J Psychosoc Nurs Ment Health Serv; 1993 Sep; 31(9):14-8. PubMed ID: 7901407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia.
    Schwartz BL; Fay-McCarthy M; Kendrick K; Rosse RB; Deutsch SI
    Clin Neuropharmacol; 1997 Aug; 20(4):364-70. PubMed ID: 9260735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of nifedipine on the effectiveness of antipsychotic therapy in schizophrenia].
    Dzhuga NP; Kozlovskiĭ VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):32-5. PubMed ID: 19738566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics.
    Shenoy RS; Sadler AG; Goldberg SC; Hamer RM; Ross B
    J Clin Psychopharmacol; 1981 May; 1(3):141-5. PubMed ID: 6117584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.